Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 41 pages report, published by Global Markets Direct

Keywords : Vaginal Atrophy (Atrophic Vaginitis) Therapeutic Products under Development, Key Players in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Overview, Vaginal Atrophy (Atrophic Vaginitis) Pipeline, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Assessment

Report ThumbnailSeptember-2013
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis). Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginal Atrophy (Atrophic Vaginitis).
- A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2013 7
  • Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Route of Administration, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Molecule Type, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 23
  • List of Tables
  • Number of Products Under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2013 7
  • Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Bayer AG, H2 2013 15
  • Foamix Ltd., H2 2013 16
  • Pantarhei Bioscience BV, H2 2013 17
  • Hygeia Therapeutics, Inc., H2 2013 18
  • Assessment by Monotherapy Products, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 23
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Drug Profile Updates 34
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Dormant Products 35
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Vaginal Atrophy (Atrophic Vaginitis) Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) 7
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Products under Development by Companies 14
  • Companies Involved in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Development 15
  • Bayer AG 15
  • Foamix Ltd. 16
  • Pantarhei Bioscience BV 17
  • Hygeia Therapeutics, Inc. 18
  • Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • E-4 - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • HYG-102 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • HYG-101 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • prasterone - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • oxytocin - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • TX-12004HR - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • estradiol hemihydrate - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Drug Profile Updates 34
  • Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Dormant Products 35
  • Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 36
  • Featured News & Press Releases 36
  • Aug 12, 2013: TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate 36
  • Jun 14, 2013: TherapeuticsMD Announces FDA Accepts IND Application For TX12-004HR 36
  • Mar 27, 2013: Shionogi Announces EMA Acceptance Of Marketing Authorization Application For Ospemifene For Treatment Of VVA 36
  • Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden 37
  • Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency 37
  • Nov 01, 2011: Peptonic Medical Announces Results From Clinical Proof Of Principle Study Of Oxytocin For Treatment Of vaginal atrophy 37
  • Apr 29, 2011: Peptonic Medical Signs Agreement With Recipharm For Production And Development Of Vagitocin For Clinical Study Program 37
  • Mar 10, 2011: Peptonic Medical Recruits Last Patient In Clincial Study Of Oxytocin For Treatment Of Vaginal Atrophy 37
  • Nov 10, 2010: Hygeia Therapeutics Announces Successful Completion Of Preclinical Studies For HYG-102 38
  • May 12, 2010: Ospemifene May Be Safe, Effective for Vulvovaginal Atrophy 38
  • Appendix 40
  • Methodology 40
  • Coverage 40
  • Secondary Research 40
  • Primary Research 40
  • Expert Panel Validation 40
  • Contact Us 41
  • Disclaimer 41

Please select a license type

Share

Related Products

Global Markets DirectVaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013Product ThumbnailVaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2013, Industry ReportProduct #: 113337
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved